Close Window

References

  1. Fuller DS, Pisoni RL, Bieber BA, Gillespie BW, Robinson BM. The DOPPS practice monitor for US dialysis care: trends through December 2011 [published online ahead of print November 5, 2012]. Am J Kidney Dis. doi:10.1053/j.ajkd.2012.10.002.
  2. Data on file. Amgen; [OutcomesPlus database; July 2014].
Return to Previous Page

The nephrology landscape continues to evolve1

Hemoglobin (Hb) levels in 2011 and 20142

Data are from OutcomesPlus, a national database of clinical data from patients receiving dialysis in facilities across the United States, excluding hospital and governmental entity patients. It contains information on approximately 80% to 85% of the entire US dialysis population. Subjects were categorized based on their mean Hb measurement during the first quarter.

IMPORTANT SAFETY INFORMATION

WARNING - Chronic Kidney Disease:
  • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
  • No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.
  • Use the lowest EPOGEN® dose sufficient to reduce the need for red blood cell (RBC) transfusions.


Scroll down for additional Important Safety Information